Defining novel transcriptional regulatory mechanisms via nuclear non-coding RNA involved in breast cancer recurrence

2019 Fiscal Year Final Research Report

• Project/Area Number: 19K21184
• Project/Area Number (Other): 18H06059 (2018)
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund (2019); Single-year Grants (2018)
• Review Section: 0701:Biology at molecular to cellular levels, and related fields
• Research Institution: Japanese Foundation for Cancer Research
• Principal Investigator: Ichikawa Yuichi 公益財団法人がん研究会, がん研究所 がん生物部, 研究員 (20632160)
• Project Period (FY): 2018-08-24 – 2020-03-31
• Keywords: ノンコーディングRNA / クロマチン / ER陽性乳がん / ESR1 / エピジェネティクス / 細胞核

Outline of Final Research Achievements

It has been proposed that ELEANOR non-coding RNAs may be involved in the recurrence of estrogen receptor (ER)-positive breast cancer by activating transcription of the ESR1 gene, which encodes ER. In this study, using chromatin isolation by RNA purification （ChIRP） method, I have revealed genomic regions associated with ELEANOR RNAs. Also, I have identified several drugs that inhibit ELEANOR's function.

Free Research Field

分子生物学

Academic Significance and Societal Importance of the Research Achievements

エレノアRNAは細胞のがん化や乳がんの治療耐性化との関与が示唆されていることから、本研究によって得られる成果は、がん細胞が治療抵抗性を獲得するメカニズムの一端を明らかにするものであり、再発がんの診断や治療標的の同定につながると期待される。